Nanotherapeutic strategy against glioblastoma using enzyme inhibitors
Glioblastoma is the most aggressive brain cancer and thus patients with glioblastoma have a severely low 5-year survival rate (
Gespeichert in:
| Veröffentlicht in: | Biomedicine & pharmacotherapy 2024-12, Vol.181, p.117713, Article 117713 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | 117713 |
| container_title | Biomedicine & pharmacotherapy |
| container_volume | 181 |
| creator | Thiruvengadam, Rekha Dareowolabi, Boluwatife Olamide Moon, Eun-Yi Kim, Jin Hee |
| description | Glioblastoma is the most aggressive brain cancer and thus patients with glioblastoma have a severely low 5-year survival rate ( |
| doi_str_mv | 10.1016/j.biopha.2024.117713 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3140887538</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0753332224015993</els_id><sourcerecordid>3140887538</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1564-2ec252da2416e64cdd74fde029c78581463d0e4170caedee8e9c8efb253ae53a3</originalsourceid><addsrcrecordid>eNp9kMtOwzAQRS0EoqXwBwhlySbFrzjpBglV5SFVsIG15diT1lUSB9tBKl9PqhSWLEazOXeu5iB0TfCcYCLudvPSum6r5hRTPickzwk7QVOyyHAqMM5P0RTnGUsZo3SCLkLYYYwzwYpzNGELQTIi-BStXlXr4ha86qCPVichehVhs0_URtk2xGRTW1fWKkTXqKQPtt0k0H7vG0hsu7Wljc6HS3RWqTrA1XHP0Mfj6n35nK7fnl6WD-tUk0zwlIKmGTWKciJAcG1MzisDmC50XmQF4YIZDJzkWCswAAUsdAFVSTOmYBg2Q7fj3c67zx5ClI0NGupateD6IBnhuCiGr4sB5SOqvQvBQyU7bxvl95JgeRAod3IUKA8C5ShwiN0cG_qyAfMX-jU2APcjAMOfXxa8DNpCq8FYDzpK4-z_DT9_SISB</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3140887538</pqid></control><display><type>article</type><title>Nanotherapeutic strategy against glioblastoma using enzyme inhibitors</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Thiruvengadam, Rekha ; Dareowolabi, Boluwatife Olamide ; Moon, Eun-Yi ; Kim, Jin Hee</creator><creatorcontrib>Thiruvengadam, Rekha ; Dareowolabi, Boluwatife Olamide ; Moon, Eun-Yi ; Kim, Jin Hee</creatorcontrib><description>Glioblastoma is the most aggressive brain cancer and thus patients with glioblastoma have a severely low 5-year survival rate (<5 %). Glioblastoma damages neural centers, causing severe depression, anxiety, and cognitive disorders. Glioblastoma is highly resistant to most of available anti-tumor medications, due to heterogeneity of glioblastoma as well as the presence of stem-like cells. To overcome the challenges in the current medications against glioblastoma, novel medications that are effective in treating the aggressive and heterogenous glioblastoma should be developed. Enzyme inhibitor and nanomedicine have been getting attention because of effective anticancer efficacies of enzyme inhibitors and a role of nanomedicine as effective carrier of chemotherapeutic drugs by targeting specific tumor areas. Furthermore, a tumor-initiating neuroinflammatory microenvironment, which is crucial for glioblastoma progression, was linked with several carcinogenesis pathways. Therefore, in this review, first we summarize neuroinflammation and glioblastoma-related neuropathways. Second, we discuss the importance of enzyme inhibitors targeting specific proteins in relation with neuroinflammation and glioblastoma-related molecular mechanisms. Third, we summarize recent findings on the significance of nanotherapeutic anticancer drugs developed using natural or synthetic enzyme inhibitors against glioblastoma as well as currently available Food and Drug Administration (FDA)-approved drugs against glioblastoma.
[Display omitted]
●Glioblastoma progresses rapidly and damages neural centers.●Patients with glioblastoma have <5 % of 5-year survival rate.●Neuropathways related with glioblastoma progression could be controlled.●Enzyme inhibitors can inhibit signaling in glioblastoma-related neuropathways.●Nanomedicine can deliver enzyme inhibitors specifically targeting tumor sites.</description><identifier>ISSN: 0753-3322</identifier><identifier>ISSN: 1950-6007</identifier><identifier>EISSN: 1950-6007</identifier><identifier>DOI: 10.1016/j.biopha.2024.117713</identifier><identifier>PMID: 39615164</identifier><language>eng</language><publisher>France: Elsevier Masson SAS</publisher><subject>Animals ; Antineoplastic Agents - pharmacology ; Antineoplastic Agents - therapeutic use ; Brain Neoplasms - drug therapy ; Brain Neoplasms - mortality ; Enzyme inhibitor ; Enzyme Inhibitors - pharmacology ; Enzyme Inhibitors - therapeutic use ; Glioblastoma ; Glioblastoma - drug therapy ; Glioblastoma - mortality ; Humans ; Nanomedicine - methods ; Nanoparticles ; Nanotherapeutics ; Neuroinflammation ; Tumor Microenvironment - drug effects</subject><ispartof>Biomedicine & pharmacotherapy, 2024-12, Vol.181, p.117713, Article 117713</ispartof><rights>2024 The Authors</rights><rights>Copyright © 2024 The Authors. Published by Elsevier Masson SAS.. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c1564-2ec252da2416e64cdd74fde029c78581463d0e4170caedee8e9c8efb253ae53a3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0753332224015993$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>314,776,780,3537,27903,27904,65309</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39615164$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Thiruvengadam, Rekha</creatorcontrib><creatorcontrib>Dareowolabi, Boluwatife Olamide</creatorcontrib><creatorcontrib>Moon, Eun-Yi</creatorcontrib><creatorcontrib>Kim, Jin Hee</creatorcontrib><title>Nanotherapeutic strategy against glioblastoma using enzyme inhibitors</title><title>Biomedicine & pharmacotherapy</title><addtitle>Biomed Pharmacother</addtitle><description>Glioblastoma is the most aggressive brain cancer and thus patients with glioblastoma have a severely low 5-year survival rate (<5 %). Glioblastoma damages neural centers, causing severe depression, anxiety, and cognitive disorders. Glioblastoma is highly resistant to most of available anti-tumor medications, due to heterogeneity of glioblastoma as well as the presence of stem-like cells. To overcome the challenges in the current medications against glioblastoma, novel medications that are effective in treating the aggressive and heterogenous glioblastoma should be developed. Enzyme inhibitor and nanomedicine have been getting attention because of effective anticancer efficacies of enzyme inhibitors and a role of nanomedicine as effective carrier of chemotherapeutic drugs by targeting specific tumor areas. Furthermore, a tumor-initiating neuroinflammatory microenvironment, which is crucial for glioblastoma progression, was linked with several carcinogenesis pathways. Therefore, in this review, first we summarize neuroinflammation and glioblastoma-related neuropathways. Second, we discuss the importance of enzyme inhibitors targeting specific proteins in relation with neuroinflammation and glioblastoma-related molecular mechanisms. Third, we summarize recent findings on the significance of nanotherapeutic anticancer drugs developed using natural or synthetic enzyme inhibitors against glioblastoma as well as currently available Food and Drug Administration (FDA)-approved drugs against glioblastoma.
[Display omitted]
●Glioblastoma progresses rapidly and damages neural centers.●Patients with glioblastoma have <5 % of 5-year survival rate.●Neuropathways related with glioblastoma progression could be controlled.●Enzyme inhibitors can inhibit signaling in glioblastoma-related neuropathways.●Nanomedicine can deliver enzyme inhibitors specifically targeting tumor sites.</description><subject>Animals</subject><subject>Antineoplastic Agents - pharmacology</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Brain Neoplasms - drug therapy</subject><subject>Brain Neoplasms - mortality</subject><subject>Enzyme inhibitor</subject><subject>Enzyme Inhibitors - pharmacology</subject><subject>Enzyme Inhibitors - therapeutic use</subject><subject>Glioblastoma</subject><subject>Glioblastoma - drug therapy</subject><subject>Glioblastoma - mortality</subject><subject>Humans</subject><subject>Nanomedicine - methods</subject><subject>Nanoparticles</subject><subject>Nanotherapeutics</subject><subject>Neuroinflammation</subject><subject>Tumor Microenvironment - drug effects</subject><issn>0753-3322</issn><issn>1950-6007</issn><issn>1950-6007</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kMtOwzAQRS0EoqXwBwhlySbFrzjpBglV5SFVsIG15diT1lUSB9tBKl9PqhSWLEazOXeu5iB0TfCcYCLudvPSum6r5hRTPickzwk7QVOyyHAqMM5P0RTnGUsZo3SCLkLYYYwzwYpzNGELQTIi-BStXlXr4ha86qCPVichehVhs0_URtk2xGRTW1fWKkTXqKQPtt0k0H7vG0hsu7Wljc6HS3RWqTrA1XHP0Mfj6n35nK7fnl6WD-tUk0zwlIKmGTWKciJAcG1MzisDmC50XmQF4YIZDJzkWCswAAUsdAFVSTOmYBg2Q7fj3c67zx5ClI0NGupateD6IBnhuCiGr4sB5SOqvQvBQyU7bxvl95JgeRAod3IUKA8C5ShwiN0cG_qyAfMX-jU2APcjAMOfXxa8DNpCq8FYDzpK4-z_DT9_SISB</recordid><startdate>202412</startdate><enddate>202412</enddate><creator>Thiruvengadam, Rekha</creator><creator>Dareowolabi, Boluwatife Olamide</creator><creator>Moon, Eun-Yi</creator><creator>Kim, Jin Hee</creator><general>Elsevier Masson SAS</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>202412</creationdate><title>Nanotherapeutic strategy against glioblastoma using enzyme inhibitors</title><author>Thiruvengadam, Rekha ; Dareowolabi, Boluwatife Olamide ; Moon, Eun-Yi ; Kim, Jin Hee</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1564-2ec252da2416e64cdd74fde029c78581463d0e4170caedee8e9c8efb253ae53a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Animals</topic><topic>Antineoplastic Agents - pharmacology</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Brain Neoplasms - drug therapy</topic><topic>Brain Neoplasms - mortality</topic><topic>Enzyme inhibitor</topic><topic>Enzyme Inhibitors - pharmacology</topic><topic>Enzyme Inhibitors - therapeutic use</topic><topic>Glioblastoma</topic><topic>Glioblastoma - drug therapy</topic><topic>Glioblastoma - mortality</topic><topic>Humans</topic><topic>Nanomedicine - methods</topic><topic>Nanoparticles</topic><topic>Nanotherapeutics</topic><topic>Neuroinflammation</topic><topic>Tumor Microenvironment - drug effects</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Thiruvengadam, Rekha</creatorcontrib><creatorcontrib>Dareowolabi, Boluwatife Olamide</creatorcontrib><creatorcontrib>Moon, Eun-Yi</creatorcontrib><creatorcontrib>Kim, Jin Hee</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Biomedicine & pharmacotherapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Thiruvengadam, Rekha</au><au>Dareowolabi, Boluwatife Olamide</au><au>Moon, Eun-Yi</au><au>Kim, Jin Hee</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Nanotherapeutic strategy against glioblastoma using enzyme inhibitors</atitle><jtitle>Biomedicine & pharmacotherapy</jtitle><addtitle>Biomed Pharmacother</addtitle><date>2024-12</date><risdate>2024</risdate><volume>181</volume><spage>117713</spage><pages>117713-</pages><artnum>117713</artnum><issn>0753-3322</issn><issn>1950-6007</issn><eissn>1950-6007</eissn><abstract>Glioblastoma is the most aggressive brain cancer and thus patients with glioblastoma have a severely low 5-year survival rate (<5 %). Glioblastoma damages neural centers, causing severe depression, anxiety, and cognitive disorders. Glioblastoma is highly resistant to most of available anti-tumor medications, due to heterogeneity of glioblastoma as well as the presence of stem-like cells. To overcome the challenges in the current medications against glioblastoma, novel medications that are effective in treating the aggressive and heterogenous glioblastoma should be developed. Enzyme inhibitor and nanomedicine have been getting attention because of effective anticancer efficacies of enzyme inhibitors and a role of nanomedicine as effective carrier of chemotherapeutic drugs by targeting specific tumor areas. Furthermore, a tumor-initiating neuroinflammatory microenvironment, which is crucial for glioblastoma progression, was linked with several carcinogenesis pathways. Therefore, in this review, first we summarize neuroinflammation and glioblastoma-related neuropathways. Second, we discuss the importance of enzyme inhibitors targeting specific proteins in relation with neuroinflammation and glioblastoma-related molecular mechanisms. Third, we summarize recent findings on the significance of nanotherapeutic anticancer drugs developed using natural or synthetic enzyme inhibitors against glioblastoma as well as currently available Food and Drug Administration (FDA)-approved drugs against glioblastoma.
[Display omitted]
●Glioblastoma progresses rapidly and damages neural centers.●Patients with glioblastoma have <5 % of 5-year survival rate.●Neuropathways related with glioblastoma progression could be controlled.●Enzyme inhibitors can inhibit signaling in glioblastoma-related neuropathways.●Nanomedicine can deliver enzyme inhibitors specifically targeting tumor sites.</abstract><cop>France</cop><pub>Elsevier Masson SAS</pub><pmid>39615164</pmid><doi>10.1016/j.biopha.2024.117713</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0753-3322 |
| ispartof | Biomedicine & pharmacotherapy, 2024-12, Vol.181, p.117713, Article 117713 |
| issn | 0753-3322 1950-6007 1950-6007 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_3140887538 |
| source | MEDLINE; Elsevier ScienceDirect Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals |
| subjects | Animals Antineoplastic Agents - pharmacology Antineoplastic Agents - therapeutic use Brain Neoplasms - drug therapy Brain Neoplasms - mortality Enzyme inhibitor Enzyme Inhibitors - pharmacology Enzyme Inhibitors - therapeutic use Glioblastoma Glioblastoma - drug therapy Glioblastoma - mortality Humans Nanomedicine - methods Nanoparticles Nanotherapeutics Neuroinflammation Tumor Microenvironment - drug effects |
| title | Nanotherapeutic strategy against glioblastoma using enzyme inhibitors |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-28T04%3A53%3A47IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Nanotherapeutic%20strategy%20against%20glioblastoma%20using%20enzyme%20inhibitors&rft.jtitle=Biomedicine%20&%20pharmacotherapy&rft.au=Thiruvengadam,%20Rekha&rft.date=2024-12&rft.volume=181&rft.spage=117713&rft.pages=117713-&rft.artnum=117713&rft.issn=0753-3322&rft.eissn=1950-6007&rft_id=info:doi/10.1016/j.biopha.2024.117713&rft_dat=%3Cproquest_cross%3E3140887538%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3140887538&rft_id=info:pmid/39615164&rft_els_id=S0753332224015993&rfr_iscdi=true |